Bacitracin
- Generic Name
- Bacitracin
- Brand Names
- Baciguent, Baciject, Cortisporin, Diosporin, Diphen, Neo-polycin, Neo-polycin HC, Neosporin Ointment, Neosporin Plus Maximum Strength, Neosporin Solution, Polycin-B, Polysporin, Procomycin, Rash Relief Antibacterial, Triple Antibiotic
- Drug Type
- Small Molecule
- Chemical Formula
- C66H103N17O16S
- CAS Number
- 1405-87-4
- Unique Ingredient Identifier
- DDA3RRX0P7
Overview
Bacitracin is a combination of at least 9 bacitracins. 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.
Background
Bacitracin is a combination of at least 9 bacitracins. 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.
Indication
Bacitracin is indicated in topical formulations for acute and chronic localized skin infections. Occasionally, it is also used intramuscularly for infantile streptococcal pneumonia and empyema. Bacitracin is also formulated as an ointment with neomycin and polymyxin B for over the counter use. A bacitracin ointment formulated with neomycin and polymyxin B along with hydrocortisone is indicated for the treatment of corticosteroid responsive dermatoses with secondary infection.
Associated Conditions
- Acne
- Bacterial Infections of the Intestine
- Empyema
- Eye Infections
- Infection
- Inflammatory Reaction caused by Acne
- Ocular Inflammatory Disease
- Pneumonia
- Skin Ulcer
- Wound
- Wound Infections
- Corticosteroid-responsive dermatoses
- Infection in minor cuts, scrapes, or burns
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.